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Introduction {#s1}
============

The epidemiology of hepatitis C virus (HCV) infection in persons living with human immunodeficiency virus (HIV) in Western countries has changed profoundly in the last 15 years [@pone.0116226-Centers1]--[@pone.0116226-Witt1]. Outbreaks of acute HCV infection have been reported in HIV-positive men who have sex with men (MSM) from the mid-2000s onwards in large cities in Europe [@pone.0116226-Bottieau1]--[@pone.0116226-Gotz1], [@pone.0116226-vandeLaar2], [@pone.0116226-Laguno1] and the United States (US) [@pone.0116226-Centers1] and decreases in the numbers of injecting drug users (IDU) in industrialized countries have led to decreases in HCV serial prevalence [@pone.0116226-PerezCachafeiro1]--[@pone.0116226-Spradling1].

The impact of these HCV outbreaks on the global epidemiology of HCV infection, particularly among HIV-positive patients, is yet to be described. In spite of the relevance of HCV co-infection [@pone.0116226-Hernando1], surveillance of HCV is not sufficiently developed in most European countries. Several European cohort studies have described increasing rates of HCV diagnoses as well as of HCV seroconversions in MSM since the mid-eighties to current date, but more markedly from 2002 onwards [@pone.0116226-Rockstroh1], [@pone.0116226-vandeLaar1], [@pone.0116226-vanderHelm1]--[@pone.0116226-Wandeler1]. The Multicentre AIDS Cohort Study (MACS) has reported the on-going HCV epidemic in HIV-positive MSM in the US from 1984 to 2011 but describes no actual increases of HCV infection over time [@pone.0116226-Witt1].

Early diagnosis of HCV infection is the first step to access treatment, HCV eradication and decreased on-going HCV transmission. However, though HCV testing is recommended to all HIV-positive persons, there are currently no guidelines on how often should HCV testing be repeated in HIV-positive patients in the absence of clinical symptoms.

The objective of this work is to describe the rates and risk factors of HCV diagnoses, follow-up HCV testing and HCV seroconversion from 2004 to 2011, in a multicentre cohort of HIV-positive persons in Spain. We show the results globally, for MSM and for people infected through heterosexual transmission (HTX).

Methods {#s2}
=======

CoRIS (Spanish acronym for the AIDS Research Network Cohort) is an open, prospective, multicentre cohort of adult (age 18 or older) patients with confirmed HIV infection. It includes patients who began follow-up in any of the participating sites after January 2004 while naïve to antiretroviral treatment (cART).

Ethics approval was obtained from all hospitals Ethics' Committees (see Annex for all hospitals participanting) and every patient provides a written informed consent to participate in the cohort.

A complete description of the cohort has been published elsewhere [@pone.0116226-SobrinoVegas1]. Currently, 31 groups from 28 public health-care centres within 13 of Spain's 17 Autonomous Regions participate in the cohort. Patients\' follow-up and frequency of HCV testing are established by the physician in charge as there are no standard recommendations for follow-up HCV testing in HIV-positive persons in Spain.

HIV-positive subjects were recruited from 2004 onwards up to the 31^st^ October 2011-- administrative censoring date. Eligibility criteria for these analyses required having a documented negative HCV serology before or upon cohort recruitment and at least one follow-up HCV test performed. Since eligibility for a follow-up HCV test also depends on the length of clinical follow-up and the number of visits, we further excluded patients with clinical follow-up periods under 2 years.

Definition of study outcomes {#s2a}
----------------------------

HCV diagnosis was defined based on positive HCV antibodies using a third generation EIA (enzyme immunoassay). HCV diagnoses were verified by consecutive confirmatory HCV-positive serologies, positive antigen determinations and/or HCV viral load detection. HCV diagnoses that could not be confirmed were also included, but sensitivity analyses excluding these cases were also performed.

The date of HCV diagnosis was the date the first HCV test was positive. Incidence rates of HCV diagnosis were calculated as the number of HCV diagnoses per 100 person-years at risk (p-y), and patients were considered at risk from the date of cohort entry to the date of their last negative HCV serology or the date of HCV diagnosis.

The date of HCV infection (or date of HCV seroconversion) was estimated using two different methods: a) the midpoint between the last negative and the first positive HCV test for any time window (*midpoint method*) and b) a multiple imputation technique (*multiple imputation method).* Rates of HCV infection were calculated as the number of HCV seroconversions - excluding those estimated before the date of patient's inclusion in the cohort - per 100 person-years at risk (p-y), and patients were considered at risk from the date of cohort entry to the date of their last negative HCV serology or the date of HCV infection.

Rate of follow-up HCV tests were calculated as the number of persons with follow-up HCV test in each period, per 100 person-years at risk of HCV diagnosis.

Statistical analyses {#s2b}
--------------------

Logistic regression models were fitted to evaluate sociodemographic characteristics associated with a follow-up HCV test (gender, age at cohort entry, educational level, country of origin, and transmission category -in mutually excluding categories and prioritizing those with a higher risk of transmission-).

The multiple imputation technique was performed as follows: for each diagnosis, the HCV seroconversion date (estimated date of infection) was imputed by extracting a random date from a uniform distribution between the last negative and the first positive HCV test, assuming that seroconversion was equally probable at any given moment during that time window. This process was replicated 20 times for each subject and a separate database was generated for each replica. The final estimates were the result of combining individual estimates from each replica using the procedure described by Rubin, which accounts for the observed variability between estimations in the estimation of the global variance [@pone.0116226-Rubin1].

Multivariate Poisson regression models were fitted to evaluate a priori established sociodemographic risk factors for HCV incidence and CD4 cell count, HIV Viral Load and cART, as time-changing variables.

To analyse trends in HCV incidence, Poisson regression models were used, evaluating the presence of confounding variables for the association between calendar period and HCV incidence. We obtained crude (IRR) and adjusted (aIRR) incidence rate ratios, and their confidence intervals at 95% (95%CI).

We performed various simulations to evaluate the potential source of selection bias derived from the exclusion of subjects who had not been tested for HCV infection during follow-up assuming they had a different risk of HCV infection. We assumed all subjects with a minimum of two years of follow-up had been tested for HCV infection on the date of their last clinic visit and calculated the number of simulated HCV infections for each calendar year under two different scenarios assuming high and arbitrary HCV incidence rates; (1) a constant HCV rate of 1.5 per 100 p-y, and (2) an increasing HCV rate overtime starting at 1.5 per 100 p-y in years 2004.05 mounting to 2.00 per 100 p-y in 2010--11. We aggregated these numbers to the main analyses and obtained HCV time trends under these simulated scenarios.

Finally, we conducted sensitivity analyses excluding the information of all HCV serologies performed before cohort entry; that is, limiting analyses to subjects with at least 2 HCV tests from cohort recruitment onwards.

Robust methods were used to estimate confidence intervals assuming a correlation between subjects recruited at each site, and independence between subjects recruited at different sites [@pone.0116226-Williams1]. Analyses were conducted using Stata (V.11, Stata Corporation, College Station, Texas, USA).

Results {#s3}
=======

Out of 7977 patients, baseline HCV serology was available for 7552 ([Fig. 1](#pone-0116226-g001){ref-type="fig"}). At cohort recruitment, 1227 had a positive HCV serology; prevalent cases were older and mainly IDU or ex-IDU (65%). Of the remaining 6425 patients with negative baseline HCV serology, 4124 had at least one follow-up HCV test or more than two years of follow-up ([Fig. 1](#pone-0116226-g001){ref-type="fig"}). In all, 2122 patients had at least one HCV test repeated over time. Median time between HCV serologies was 1.34 years (IQR: 0.43--2.49) and median number of serologies per patient was 2 (IQR: 2--3). Follow-up HCV testing was commoner in MSM, people under 50 years of age and non-Spanish origin ([Table 1](#pone-0116226-t001){ref-type="table"}). Further, the rate of follow-up tests increased over time, reaching up to 85 follow-up HCV test per 100 person-years in the period 2010--2011; 89 per 100 p-y for MSM and 78 per 100 p-y for the heterosexually infected ([Table 2](#pone-0116226-t002){ref-type="table"} and [Fig. 2A, 2B, 2C](#pone-0116226-g002){ref-type="fig"}). The percentage of positive HCV diagnoses among the tested individuals dropped slightly over this period (2.6% in 2004--05 to 1.6% in 2010--11).

![Patients flow-chart.](pone.0116226.g001){#pone-0116226-g001}

![Time trends of rates of HCV diagnoses, HCV infections and of follow-up HCV tests, 2004--2011.](pone.0116226.g002){#pone-0116226-g002}

10.1371/journal.pone.0116226.t001

###### Sociodemographic characteristics of 4124 patients with follow-up HCVtest or more than two years of follow-up: prevalence of repeated HCV tests and multivariable logistic regression for the odds ratio (OR) of having a subsequent HCV serology.

![](pone.0116226.t001){#pone-0116226-t001-1}

                                 Patients with follow-up HCV test or more than two years of follow-up (n = 4,124)   Adjusted OR (95% CI)                              
  ----------------------------- ---------------------------------------------------------------------------------- ---------------------- ------ ------ ------ ------ -------------------
  **SEX**                                                                                                                                                             
  Male                                                                 3356                                                 81.4           1797   53.5   1559   46.5           1
  Female                                                               768                                                  18.6           325    42.3   443    57.7   0.96 (0.78--1.17)
  **TRANSMISSION CATEGORY**                                                                                                                                           
  Heterosexuals                                                        1471                                                 35.7           621    42.2   850    57.8           1
  Injecting drug users                                                  63                                                  1.5             22    34.9    41    65.1   0.74 (0.43--1.26)
  Homo/bisexual men                                                    2461                                                 59.7           1422   57.8   1039   42.2   1.79 (1.50--2.13)
  Other/Unknown/Not available                                          129                                                  3.1             57    44.2    72    55.8   1.04 (0.72--1.51)
  **AGE AT ENTRY**                                                                                                                                                    
  \< = 30 years                                                        1423                                                 34.5           752    52.8   671    47.2   1.29 (1.02--1.65)
  31--40 years                                                         1581                                                 38.3           843    53.3   738    46.7   1.36 (1.07--1.72)
  41--50 years                                                         745                                                  18.1           370    49.7   375    50.3   1.27 (0.98--1.64)
  \>50 years                                                           375                                                  9.1            157    41.9   218    58.1           1
  **EDUCATION LEVEL**                                                                                                                                                 
  Low                                                                  1301                                                 31.5           627    48.2   674    51.8           1
  Medium                                                               1419                                                 34.4           749    52.8   670    47.2   1.00 (0.85--1.17)
  High                                                                 942                                                  22.8           533    56.6   409    43.4   1.10 (0.92--1.31)
  Not available                                                        462                                                  11.2           213    46.1   249    53.9   0.89 (0.72--1.10)
  **COUNTRY OF ORIGIN**                                                                                                                                               
  Spain                                                                2794                                                 67.7           1416   50.7   1378   49.3           1
  Other                                                                1317                                                 31.9           694    52.7   623    47.3   1.17 (1.02--1.34)
  Not available                                                         13                                                   .3             12            1                   --
  **TOTAL**                                                            4124                                                100.0           2122   51.5   2002   48.5  

10.1371/journal.pone.0116226.t002

###### Evolution of follow-up HCV testing rates, of HCV diagnosis rates and of HCV infection rates (per 100 person-years).

![](pone.0116226.t002){#pone-0116226-t002-2}

                             All subjects                                                                                                                                                                                                                                              
  ------------ ----------------------------------------- ----------------------------------- ----------------------------------------- ---------------------------------------------------- ------- -------- ------------------- ------- -------- ------------------- ------- -------- -------------------
  **PERIOD**                                                                                                                                                                                                                                                                           
  2004--05                        154                                  455.50                                   34                                              1                              4      0.88            1             7      1.54            1           8.10     1.77            1
  2006--07                        513                                  1452.58                                  35                                      1.04 (0.87--1.25)                     10      0.69    0.78 (0.30--2.05)    18      1.25    0.81 (0.39--1.66)   14.30    0.99    0.56 (0.22--1.43)
  2008--09                        950                                  2162.46                                  44                                      1.30 (1.10--1.54)                     17      0.79    0.90 (0.24--3.30)    15      0.70    0.45 (0.17--1.20)   13.80    0.64    0.36 (0.11--1.15)
  2010--11                       1379                                  1618.40                                  85                                      2.52 (2.13--2.98)                     22      1.36    1.55 (0.37--6.55)     6      0.37    0.24 (0.10--0.58)   10.50    0.65    0.37 (0.12--1.11)
  **TOTAL**                      2996                                  5688.94                                  53                                                                            53      0.93                         46      0.82                        46.70    0.83   
                     **Men who have sex with men**                                                                                                                                                                                                                                     
                **Follow-up HCV** **tests (n = 1,421)**   **HCV diagnoses** **(n = 1,421)**             **HCV Infections**                                                                                                                                                             
                                                                                              **Midpoint** **Method** **(n = 1,416)**   **Multiple** **Imputation** **Method (n = 1,421)**                                                                                             
                                 **n**                                 **p-y**                                **IR**                                     **IRR (95% CI)**                    **n**   **IR**   **IRR (95% CI)**    **n**   **IR**   **IRR (95% CI)**    **n**   **IR**   **IRR (95% CI)**
  **PERIOD**                                                                                                                                                                                                                                                                           
  2004--05                        83                                   263.70                                   31                                              1                              2      0.76            1             3      1.14            1           2.90     1.06            1
  2006--07                        307                                  885.74                                   35                                      1.10 (0.86--1.40)                      4      0.45    0.60 (0.17--2.07)     6      0.68    0.60 (0.18--1.96)   6.10     0.68    0.65 (0.13--3.23)
  2008--09                        597                                  1374.98                                  43                                      1.38 (1.10--1.74)                      9      0.65    0.86 (0.26--2.88)     9      0.66    0.58 (0.25--1.33)   7.35     0.52    0.50 (0.12--2.14)
  2010--11                        966                                  1090,28                                  89                                      2.81 (2.25--3.52)                     12      1.10    1.45 (0.31--6.82)     3      0.28    0.24 (0.06--0.90)   5.40     0.49    0.46 (0.09--2.31)
  **TOTAL**                      1953                                  3614.70                                  54                                                                            27      0.75                         21      0.58                        21.75    0.60   
                   **Heterosexually acquired cases**                                                                                                                                                                                                                                   
                 **Follow-up HCV** **tests (n = 621)**     **HCV diagnoses** **(n = 621)**              **HCV Infections**                                                                                                                                                             
                                                                                               **Midpoint** **Method** **(n = 620)**     **Multiple** **Imputation** **Method (n = 621)**                                                                                              
                                 **n**                                 **p-y**                                **IR**                                     **IRR (95% CI)**                    **n**   **IR**   **IRR (95% CI)**    **n**   **IR**   **IRR (95% CI)**    **n**   **IR**   **IRR (95% CI)**
  **PERIOD**                                                                                                                                                                                                                                                                           
  2004--05                        64                                   168.60                                   38                                              1                              2      1.19            1             3      1.79            1           4.40     2.55            1
  2006--07                        185                                  515.81                                   36                                      0.94 (0.71--1.26)                      5      0.97    0.82 (0.14--4.78)    11      2.16    1.21 (0.27--5.38)   7.45     1.43    0.56 (0.12--2.63)
  2008--09                        319                                  715.35                                   45                                      1.17 (0.90--1.54)                      7      0.98    0.82 (0.08--8.11)     3      0.43    0.24 (0.03--1.75)   4.20     0.57    0.22 (0.03--1.43)
  2010--11                        365                                  470.40                                   78                                      2.04 (1.57--2.67)                      6      1.28    1.08 (0.11--0.24)     2      0.43    0.24 (0.10--0.58)   2.90     0.59    0.23 (0.06--0.98)
  **TOTAL**                       933                                  1870.15                                  50                                                                            20      1.07                         19      1.03                        18.95    1.03   

The majority of these 2122 persons were men (85%), infected through sexual transmission (67% MSM and 29.3% HTX), and of Spanish origin (67%). Overall, 35% were under 30 and 25% over 50, with ages between 18 and 77 ([Table 1](#pone-0116226-t001){ref-type="table"}). Median CD4 count at recruitment was 399 (IQR: 224--592), median viral load was 4.6 log (IQR: 4.06--5.15) and 76% started cART during follow-up.

These 2122 individuals added up to 5689 p-y in whom 53 HCV diagnoses were observed. In 48 cases, diagnosis could be confirmed and in five no further serologic determinations had been performed. HCV diagnosis rate was IR = 0.93 (95%CI: 0.71--1.22) ([Table 2](#pone-0116226-t002){ref-type="table"}). Global HCV diagnosis rates increased from 0.88 in 2004--05 to 1.36 in 2010--11 (IRR 1.55; 95%CI: 0.37--6.55) ([Table 2](#pone-0116226-t002){ref-type="table"}, [Fig. 2A](#pone-0116226-g002){ref-type="fig"}). Among MSM, rates of HCV diagnosis increased from 0.76 to 1.10 per 100 p-y (IRR 1.45; 95%CI: 0.31--6.82) ([Table 2](#pone-0116226-t002){ref-type="table"}, [Fig. 2B](#pone-0116226-g002){ref-type="fig"}) and in HTX from 1.19 to 1.28 per 100 p-y (IRR 1.08; 95%CI: 0.11--10.24) ([Table 2](#pone-0116226-t002){ref-type="table"}, [Fig. 2C](#pone-0116226-g002){ref-type="fig"}).

Using the multiple imputation method, infection rate was 0.83 (95%CI: 0.61--1.13) after excluding the one individual with all imputed seroconversion dates before cohort entry. HCV infection rate decreased from 1.77 to 0.65 per 100 p-y (IRR = 0.37; 95%CI: 0.12--1.11) ([Table 2](#pone-0116226-t002){ref-type="table"}, [Fig. 2A](#pone-0116226-g002){ref-type="fig"}). Among MSM it decreased from 1.06 to 0.49 per 100 p-y (IRR 0.46; 95%CI: 0.09--2.31) ([Table 2](#pone-0116226-t002){ref-type="table"}, [Fig. 2B](#pone-0116226-g002){ref-type="fig"}). In HTX it decreased from 2.55 to 0.59 per 100 p-y (IRR 0.23; 95%CI: 0.06--0.98) ([Table 2](#pone-0116226-t002){ref-type="table"}, [Fig. 2C](#pone-0116226-g002){ref-type="fig"}). Using the midpoint method, infection rate was 0.82 per 100 p-y (95%CI: 0.61--1.09) -seven patients were excluded because their seroconversion date was before cohort entry-. Time trends of HCV infection rate using this method are showed in [Table 2](#pone-0116226-t002){ref-type="table"} and [Fig. 2](#pone-0116226-g002){ref-type="fig"}. Only unadjusted results are shown, as they were not confounded by any of the variables studied.

Factors independently associated with higher HCV infection were: being an IDU (aIRR 9.63; 95%CI: 2.88--32.19) and, though not reaching statistical significance, age 41--50 (aIRR 1.66; 95%CI: 0.85--3.24) and CD4 cell count below 200 cells/mm^3^ (aIRR 1.93; 95%CI: 0.90--4.15) ([Table 3](#pone-0116226-t003){ref-type="table"}). In analyses restricted to MSM, the only factor associated with a higher HCV infection was age 41--50 (IRR 3.21; 95%CI: 1.66--6.23). Among HTX, two factors showed independent association with higher HCV infection rate: female sex (aIRR 2.35; 95%CI: 1.03--5.34) and CD4 cell count below 200 cells/mm^3^ (aIRR 2.39; 95%CI: 0.83--6.89).

10.1371/journal.pone.0116226.t003

###### Rates and associated risk factors of HCV infection.
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                                        ALL subjects (n = 2,115)                                                             
  --------------------------- --------------------------------------------- ------------------ -------- -------------------- --------------------
  **SEX**                                                                                                                    
  Male                                             33                            4694.28         0.70            1                    1
  Female                                           13                             941.43         1.38    1.96 (1.03--3.76)    1.58 (0.78--3.20)
  **TRANSMISSION CATEGORY**                                                                                                  
  Heterosexuals                                    19                            1846.42         1.03            1                    1
  Injecting drug users                              5                             53.31          9.38    9.11 (2.86--29.08)   9.63 (2.88--32.19)
  Homo/bisexual men                                21                            3592.28         0.58    0.57 (0.24--1.36)    0.81 (0.29--2.27)
  Other/Unknown                                     1                             143.70         0.70    0.68 (0.10--4.79)    0.77 (0.11--5.50)
  **AGE AT ENTRY**                                                                                                           
  \< = 30 years                                    11                            1866.73         0.59            1                    1
  31--40 years                                     19                            2350.63         0.81    1.37 (0.57--3.30)    1.38 (0.57--3.30)
  41--50 years                                     12                             960.44         1.25    2.12 (1.15--3.90)    1.66 (0.85--3.24)
  \>50 years                                        4                             457.91         0.87    1.48 (0.68--3.24)    1.29 (0.53--3.14)
  **CD4+ T-Cell Count**                                                                                                      
  \<200 cells/mm^3^                                 8                             455.76         1.76    2.36 (1.17--4.75)    1.93 (0.90--4.15)
  \> = 200 cells/mm^3^                             38                            5100.96         0.74            1                    1
  Not available                                     0                             79.00          0.00                        
  **TOTAL**                                        46                            5635.72         0.82                        
                                **Men who have sex with men (n = 1,416)**                                                    
                                             **Infections**                  **Person-years**   **IR**    **IRR (CI 95%)**    **aIRR (CI 95%)**
  **AGE AT ENTRY**                                                                                                           
  \< = 30 years                                     5                            1314.77         0.38            1                    1
  31--40 years                                      9                            1562.66         0.58    1.51 (0.44--5.22)    1.51 (0.44--5.22)
  41--50 years                                      6                             490.79         1.22    3.21 (1.66--6.23)    3.21 (1.66--6.23)
  \>50 years                                        1                             224.06         0.45    1.17 (0.24--5.67)    1.17 (0.24--5.67)
  **TOTAL**                                        21                            3592.28         0.58                        
                               **Heterosexually acquired cases (n = 620)**                                                   
                                             **Infections**                  **Person-years**   **IR**    **IRR (CI 95%)**    **aIRR (CI 95%)**
  **SEX**                                                                                                                    
  Male                                              6                             943.48         0.64            1                    1
  Female                                           13                             902.95         1.44    2.26 (1.01--5.05)    2.35 (1.03--5.34)
  **CD4+ T-Cell Count**                                                                                                      
  \<200 cells/mm^3^                                 5                             247.88         2.02    2.26 (0.78--6.53)    2.39 (0.83--6.89)
  \> = 200 cells/mm^3^                             14                            1569.37         0.89            1                    1
  Not available                                     0                             29.17          0.00           ---                  ---
  **TOTAL**                                        19                            1846.42         1.03                        

\*The table shows all the variables included in the final multivariables models.

The analyses of the associated risk factors yielded similar results using the two methods to estimate HCV seroconversion, for the cohort as a whole and for the two transmission categories analysed separately (Table 4 in [S1 File](#pone.0116226.s001){ref-type="supplementary-material"}).

Results from simulation and sensitivity analyses {#s3a}
------------------------------------------------

The simulation analysis assuming a constant HCV infection rate at 1.5 per 100 p-y throughout the study period among patients without serological follow-up, still showed a decrease in global infections rates. Assuming an increasing trend in HCV infection, from 1.5 in 2004/05 to 2.0 per 100 p-y in 2010/11, did not led to increases in HCV global infections rates, either (Tables 5a--5b in [S2 File](#pone.0116226.s002){ref-type="supplementary-material"}).

Excluding the HCV serologies performed before cohort entry restricted the sample to 1490 patients and 4003 p-y of serological follow-up. Sensitivity analyses showed very similar results for the incidence rate and risk factors, as well as for the time-trend analyses, although some were underpowered (Tables 6--7 and Figure 3 in [S3 File](#pone.0116226.s003){ref-type="supplementary-material"}). Excluding non-confirmed HCV diagnoses did not change findings either (Tables 8--9 and Figure 4 in [S4 File](#pone.0116226.s004){ref-type="supplementary-material"}).

Discussion {#s4}
==========

The HCV infection rate observed in our cohort is 0.82 per 100 p-y globally, 9.4 per 100 p-y in IDU, 0.6 per 100 p-y in MSM and heterosexually infected men, and 1.4 per 100 p-y in heterosexually infected women. We report increases in the rates of HCV diagnoses in the last years which seem secondary to intensification of HCV follow-up testing but not to rises in HCV infection rates in a cohort of HIV-positive patients between 2004 and 2011 in Spain.

Injecting drug use remains the strongest risk factor for HCV infection rates, though the number of IDUs is now very low in the cohort. MSM aged 41--50, female heterosexuals and heterosexuals with CD4 cell count below 200 cells/mm^3^ had increased HCV infection rates.

HCV infection rates are, similar to those reported by earlier works conducted in HIV positive individuals [@pone.0116226-Rockstroh1], [@pone.0116226-vandeLaar1], [@pone.0116226-Witt1], [@pone.0116226-Gamage1], [@pone.0116226-Taylor1]. Eurosida reported global IR of 0.79 per 100 p-y during 2002--2010 [@pone.0116226-Rockstroh1]. In HIV-positive MSM, Van de Laart et al. reported IR of 0.87 per 100 p-y during 2000--2003 [@pone.0116226-vandeLaar1], Taylor et al. IR = 0.51 per 100 p-y during 1996--2008 [@pone.0116226-Taylor1], Gamage et al. IR = 0.6 per 100 p-y during 2002--2010 [@pone.0116226-Gamage1] and Witt et al. reported IR = 0.52 per 100 p-y during 2005--2011 [@pone.0116226-Witt1].

The risk factors associated with HCV infection identified in these analysis are comparable to previous studies; HCV infection is far higher in IDU [@pone.0116226-vandeLaar1], [@pone.0116226-Witt1], [@pone.0116226-Gamage1], [@pone.0116226-Taylor1], [@pone.0116226-Hsieh1], [@pone.0116226-Esteban1] and, within the MSM, incidence increases with age [@pone.0116226-Gamage1] although it stabilizes after age 50. HCV infection rates were similar between MSM and men who only reported sex with women. Information bias due to under disclosure of past injecting drug use cannot be ruled out.

We have observed that the HCV infection rate in subjects with CD4 cell counts below 200 cells/mm^3^ is twice higher that of people with better immunological situation, although results did not reach statistical significance. A recently published study from the MACS describes that, in individuals with \<500 CD4 cells/mm^3^, HCV incidence was inversely associated with CD4 count [@pone.0116226-Witt1], but previous publications did not report these findings [@pone.0116226-Wandeler1], [@pone.0116226-Taylor1]. We need to take into account that the statistical power of this result is limited, as the person-time spent with CD4 cell counts below 200 cells/mm^3^ is short, and the rate of follow-up HCV test was higher in subjects with \<200CD4 (RR = 1.3; 95%CI: 1.2--1.4).

Follow-up HCV testing was more common in MSM, people under 50 years of age and non-Spanish origin. It seems that qualitative and quantitative changes regarding HCV testing have taken place in Spain in the last years. As a consequence of the alert raised by the outbreaks of HCV infection in MSM, it seems physicians are testing this group more frequently, increasing the number of positive diagnoses as well, contributing to the denominator, and thus yielding lower seroconversion rates. Further, selection bias due to more frequent and selective HCV testing to a subset of HTX in whom a higher risk of infection is perceived may also have taken place, particularly in the first period before HCV testing become more widespread. This could be the case of the female sexual partners of HCV-positive IDU. Heterosexual women had an HCV infection rate twice higher than heterosexual men, similar to the PRIMO cohort and consistent with unprotected sexual intercourse with male IDU [@pone.0116226-Ghosn1]. Unfortunately, the characteristics of the sexual partner/s of cohort members are not collected in CoRIS. The decreasing trend of HCV infection in CoRIS is concordant with the decrease in serial prevalence of HCV infection biomarkers reported by the Spanish national biosurveillance network [@pone.0116226-Informe1], as well as with the serial HCV prevalence reported in CoRIS [@pone.0116226-PerezCachafeiro1], [@pone.0116226-SerranoVillar1].

Our time-trends results need to be placed in context of works which have found an increasing HCV incidence in European countries in recent years [@pone.0116226-Rockstroh1], some of them in MSM [@pone.0116226-vandeLaar1], [@pone.0116226-vanderHelm1], [@pone.0116226-Wandeler1]. Eurosida reported an IR ranging from 0.47 to 2.34 per 100 p-y in the period 2002--2010 [@pone.0116226-Rockstroh1]. In HIV-positive MSM, Van de Laart et al. reported an IR varying from 0.08 to 0.87 per 100 p-y in 1984--2003 [@pone.0116226-vandeLaar1], the Swiss HIV Cohort an IR from 0.23 to 4.09 per 100 p-y in 1998--2011 [@pone.0116226-Wandeler1], and in CASCADE Collaboration IR ranged depending on the method used from 1.6 and 3.0 in 2005 to 2.34 and 5.11 per 100 p-y in 2007 [@pone.0116226-vanderHelm1]. In HTX, the Swiss HIV Cohort reported a stabilized IR of less than 0.5 per 100 p-y [@pone.0116226-Wandeler1].

For all groups and for MSM, we observe an increase of 50% in HCV diagnoses rates that did not reach statistical significance; the decrease in HCV infections was not significant either. This indicates that more cases are being diagnosed in recent years, but that does not mean more infections are necessarily occurring. In HTX, where the decrease in HCV seroconversions reaches statistical significance, the increased follow-up HCV testing does not lead to changes in the diagnosis rates.

For time-trends analysis we considered multiple imputation as the most appropriate method because the midpoint method underestimates the rates in the two extremes of the timeframe.

As a limitation, we acknowledge that HCV testing in our cohort was performed according to clinical criteria, rather than following a pre-specified screening scheme, so we cannot rule out that those with available follow-up serologies are those in which a higher probability of HCV infection was suspected; thus we could have overestimated the rates of HCV diagnoses and of HCV infection in our cohort. We think this is unlikely to having serious biased our results since the rate of patients that undergo serological follow-up has increased more than two-fold throughout the study period, to a similar degree in all transmission categories (34 to 86 per 100 p-y from 2004--05 to 2010--11), so it is possible that the non-significant increase we observe in HCV incidence is explained by an extension of serological follow-up to low-risk subjects.

Though CoRIS is not population-based, subjects included in the cohort show similar characteristics to those reported by Spanish national surveillance [@pone.0116226-VigilanciaepidemiolgicadelHIVsidaen1]. Therefore, our results can be extrapolated to the HIV-infected population in Spain. On the other hand, excluding patients' serological information previous to cohort recruitment did not affect our estimates.

In conclusion, the increases in the rates of HCV diagnoses seem secondary to intensification of HCV follow-up testing, which is unveiling previously undiagnosed subjects, and not necessarily to rises in HCV infection. Repeating HCV tests to all HIV-positive persons under follow-up has yielded an increase in the number of cases, which is relevant both for clinical and public health purposes. Further follow-up of this cohort under similar HCV testing practices will provide additional evidence on the evolution of the rates of both HCV diagnosis and HCV infection in order to issue recommendations of HCV testing strategies in the HIV-positive population.
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